Invex Therapeutics Ltd. (AU:IXC) has released an update.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Invex Therapeutics Ltd. has announced promising results from their collaboration with Tessara Therapeutics, showing that Exenatide significantly improves neuronal cell survival in a 3D human brain model of Alzheimer’s Disease. The study highlights Exenatide’s potential in increasing cell viability and its role as a GLP-1 receptor agonist in protecting against Alzheimer’s, a market valued at $17 billion in 2023. These findings could pave the way for further exploration of Exenatide in treating other neurodegenerative diseases.
For further insights into AU:IXC stock, check out TipRanks’ Stock Analysis page.